| Literature DB >> 33171998 |
Karma Yeshi1, Darren J Creek2, Dovile Anderson2, Edita Ritmejerytė1, Luke Becker1, Alex Loukas1, Phurpa Wangchuk1.
Abstract
Soil-transmitted helminths, including hookworms and whipworms, infect billions of people worldwide. Their capacity to penetrate and migrate through their hosts' tissues is influenced by the suite of molecules produced by the infective developmental stages. To facilitate a better understanding of the immunobiology and pathogenicity of human hookworms and whipworms, we investigated the metabolomes of the infective stage of Nippostrongylus brasiliensis third-stage larvae (L3) which penetrate the skin and Trichuris muris eggs which are orally ingested, using untargeted liquid chromatography-mass spectrometry (LC-MS). We identified 55 polar metabolites through Metabolomics Standard Initiative level-1 (MSI-I) identification from N. brasiliensis and T. muris infective stages, out of which seven were unique to excretory/secretory products (ESPs) of N. brasiliensis L3. Amino acids were a principal constituent (33 amino acids). Additionally, we identified 350 putative lipids, out of which 28 (all known lipids) were unique to N. brasiliensis L3 somatic extract and four to T. muris embryonated egg somatic extract. Glycerophospholipids and glycerolipids were the major lipid groups. The catalogue of metabolites identified in this study shed light on the biology, and possible therapeutic and diagnostic targets for the treatment of these critical infectious pathogens. Moreover, with the growing body of literature on the therapeutic utility of helminth ESPs for treating inflammatory diseases, a role for metabolites is likely but has received little attention thus far.Entities:
Keywords: LC-MS; Nippostrongylus brasiliensis; Trichuris muris; infective stage; lipidomic; metabolites; metabolomic; parasites
Year: 2020 PMID: 33171998 PMCID: PMC7694664 DOI: 10.3390/metabo10110446
Source DB: PubMed Journal: Metabolites ISSN: 2218-1989
Figure 1Schematic flowchart of the metabolomic and lipidomic profiling strategy applied for the infective stages of the N. brasiliensis (L3) and T. muris (embryonated eggs).
Figure 2Distribution of total putative metabolites by different metabolite classes (A) in the somatic extract of infective third-stage larvae (L3) of N. brasiliensis (NB_SE); (B) in the excretory/secretory products of N. brasiliensis L3 (NB_ESP); and (C) in the somatic extract of T. muris embryonated eggs (TM_SE).
Polar metabolites (MSI-I identified) of infective stages of N. brasiliensis (L3) and T. muris (embryonated eggs).
| Polar Metabolites | Formula a | Mass ( | Rt (min) c | KEGG ID d | Log2(FC) e | Chemical Taxonomy b | Reported Pharmacological Activities | Average Peak Area (mz/rt) | ||
|---|---|---|---|---|---|---|---|---|---|---|
| NB_SE | NB_ESP | TM_SE | ||||||||
| Adenine | C5H5N5 | 135.054 | 8.32 | C00147 | 5.23 | 6-aminopurines | Anti-inflammatory [ | 103,160,746 | 309,024 | 101,274 |
| Adenosine | C10H13N5O4 | 267.096 | 8.23 | C00212 | 5.21 | Purine nucleosides | Anti-inflammatory [ | 327,057,005 | 0 | 347,270 |
| Inosine | C10H12N4O5 | 268.080 | 10.32 | C00294 | 4.77 | Purine nucleosides | Anti-inflammatory [ | 14,631,676 | 0 | 18,472 |
| C7H15NO3 | 161.105 | 12.32 | C00487 | 4.56 | Carnitines | Anti-inflammatory [ | 81,471,762 | 1,911,162 | 125,132 | |
| Choline | C5H13NO | 103.099 | 20.72 | C00114 | 4.53 | Cholines | Anti-inflammatory [ | 82,418,790 | 0 | 129,808 |
| N(pi)-Methy | C7H11N3O2 | 169.085 | 11.58 | C01152 | 3.86 | Histidine and derivatives | N/A | 5,268,444 | 2,170,489 | 13,260 |
| Xanthine | C5H4N4O2 | 152.033 | 11.08 | C00385 | 3.62 | Xanthines | Proinflammatory [ | 37,256,722 | 3,609,773 | 103,264 |
| C4H7NO4 | 133.037 | 14.57 | C00402 | 3.52 | Aspartic acid and derivatives | Anti-inflammatory and neuroprotective [ | 3,886,437 | 402,353 | 9321 | |
| Succinate | C4H6O4 | 118.026 | 15.15 | C00042 | 3.14 | Dicarboxylic acids and derivatives | Activate inflammatory pathways [ | 29,148,318 | 5,130,431 | 99,396 |
| 5-Aminolevulinate | C5H9NO3 | 131.058 | 13.74 | C00430 | 3.11 | Delta amino acids and derivatives | Anti-inflammatory [ | 8,231,888 | 0 | 33,627 |
| Adenosine 5′-monophosphate | C10H14N5O7P | 347.063 | 13.03 | C00020 | 3.05 | Purine ribonucleoside monophosphates | Anti-inflammatory [ | 9,485,566 | 0 | 43,938 |
| Hypoxanthine | C5H4N4O | 136.038 | 9.56 | C00262 | 2.84 | Hypoxanthines | Anti-inflammatory and wound healing [ | 48,567,229 | 425,871 | 230,726 |
| Lactose | C12H22O11 | 342.116 | 15.25 | C00243 | 2.61 | O-glycosyl compounds | N/A | 94,498,840 | 420,550 | 552,215 |
| C5H9NO4 | 147.053 | 14.24 | C00025 | 2.30 | Glutamic acid and derivatives | Antioxidant [ | 16,940,920 | 4,993,538 | 104,717 | |
| C5H11NO2S | 149.051 | 10.81 | C00073 | 2.06 | Methionine and derivatives | Anti-inflammatory [ | 2,078,174 | 890,947 | 15,017 | |
| C6H9N3O2 | 155.069 | 14.25 | C00135 | 1.82 | Histidine and derivatives | Anti-inflammatory [ | 14,964,799 | 1,089,738 | 135,916 | |
| 4-Hydroxybenzoate | C7H6O3 | 138.031 | 10.37 | C00156 | 1.73 | Hydroxybenzoic acid derivatives | Neuroprotective [ | 1,566,927 | 1,019,203 | 13,620 |
| C9H11NO3 | 181.074 | 12.44 | C00082 | 1.09 | Tyrosine and derivatives | N/A | 3,708,634 | 6,686,668 | 58,822 | |
| Deoxyadenosine | C10H13N5O3 | 251.101 | 7.48 | C00559 | −1.03 | Purine 2′-deoxyribonucleosides | Cell growth inhibitor and cytotoxic [ | 628,485 | 0 | 39,096 |
| (S)-Malate | C4H6O5 | 134.021 | 16.18 | C00149 | −1.28 | Beta hydroxy acids and derivatives | N/A | 51,344,999 | 43,880,026 | 0 |
| D-Glucose 6-phosphate | C6H13O9P | 260.029 | 15.83 | C00092 | −1.66 | Hexose phosphates | N/A | 402,720 | 0 | 42,982 |
| 2-Oxoglutarate | C5H6O5 | 146.021 | 15.77 | C00026 | −1.80 | Gamma-keto acids and derivatives | Anti-inflammatory [ | 249,067 | 2,843,652 | 0 |
| C6H11NO2 | 129.079 | 11.42 | C00408 | −1.94 | N/A | 139,920 | 0 | 16,319 | ||
| Mannitol | C6H14O6 | 182.079 | 13.30 | C00392 | −2.08 | Sugar alcohol | Anti-edema [ | 299,808 | 0 | 37,781 |
| C3H7NO2 | 89.047 | 14.12 | C00041 | −2.27 | Anti-inflammatory [ | 3,102,359 | 3,529,005 | 0 | ||
| Betaine | C5H11NO2 | 117.079 | 10.39 | C00719 | −2.39 | Alpha amino acids | Neuroprotective [ | 261,777,360 | 56,072,188 | 0 |
| C6H14N2O2 | 146.105 | 22.50 | C00047 | −2.45 | Anti-inflammatory [ | 2,260,735 | 1,941,102 | 0 | ||
| C6H14N4O2 | 174.111 | 24.05 | C00062 | −2.47 | Anti-inflammatory [ | 30,934,546 | 3,589,173 | 0 | ||
| C5H10N2O3 | 146.069 | 14.44 | C00064 | −2.48 | Anti-inflammatory [ | 45,487,251 | 39,780,748 | 0 | ||
| C6H11NO4 | 161.068 | 14.47 | C00956 | −2.49 | N/A | 137,122 | 0 | 22,389 | ||
| C9H11NO2 | 165.079 | 9.35 | C00079 | −2.50 | Anti-diabetic [ | 1,534,294 | 18,355,000 | 0 | ||
| 3’,5’-Cyclic AMP | C10H12N5O6P | 329.052 | 8.72 | C00575 | −2.54 | 3′,5′-cyclic purine nucleotides | Anti-inflammatory [ | 281,873 | 0 | 57,179 |
| N-Acetylputrescine | C6H14N2O | 130.110 | 21.02 | C02714 | −2.58 | Carboximidic acids | Lung cancer biomarker [ | 125,036 | 0 | 22,355 |
| Thymine | C5H6N2O2 | 126.043 | 6.96 | C00178 | −3.62 | Hydroxypyrimidines | N/A | 169,388 | 0 | 64,297 |
| C6H13NO2 | 131.094 | 9.97 | C00123 | −4.14 | Leucine and derivatives | Analgesic and anti-inflammatory [ | 1,593,314 | 10,121,672 | 735,972 | |
| Urocanate | C6H6N2O2 | 138.043 | 10.49 | C00785 | −4.16 | Imidazolyl carboxylic acids and derivatives | Chemoattractant [ | 452,897 | 169,049 | 232,883 |
| Azelaic acid | C9H16O4 | 188.105 | 10.69 | C08261 | −4.89 | Medium-chain fatty acids | Anti-inflammatory [ | 131,028 | 874,645 | 116,635 |
| Maleic acid | C4H4O4 | 116.011 | 12.18 | C01384 | −5.67 | Dicarboxylic acids and derivatives | Inflammatory/Cytotoxic [ | 98,623 | 0 | 154,549 |
| D-Glycerate | C3H6O4 | 106.026 | 11.85 | C00258 | ns | Sugar acids and derivatives | N/A | 343,824 | 0 | 8833 |
| Homogentisate | C8H8O4 | 168.042 | 9.42 | C00544 | ns | 2(hydroxyphenyl)acetic acids | Pro-inflammatory [ | 0 | 640,416 | 0 |
| Isocitrate | C6H8O7 | 192.027 | 19.04 | C00311 | ns | Tricarboxylic acids and derivatives | N/A | 0 | 37,798,044 | 0 |
| C6H13N3O3 | 175.095 | 14.84 | C00327 | ns | Anti-inflammatory and antioxidant [ | 672,469 | 0 | 21,477 | ||
| C5H9NO2 | 115.063 | 11.96 | C00148 | ns | Proline and derivatives | Anti-inflammatory [ | 9,760,345 | 1,106,588 | 269,125 | |
| C3H7NO3 | 105.042 | 15.56 | C00065 | ns | Serine and derivatives | Modulates adaptive immunity by controlling T cell proliferative capacity [ | 337,344 | 45,878 | 6178 | |
| C4H9NO3 | 119.058 | 14.14 | C00188 | ns | Anti-inflammatory [ | 425,688 | 0 | 14,375 | ||
| C11H12N2O2 | 204.090 | 11.03 | C00078 | ns | Indolyl carboxylic acids and derivatives | Anti-inflammatory [ | 2,002,647 | 1,435,161 | 127,849 | |
| C5H11NO2 | 117.079 | 11.76 | C00183 | ns | Valine and derivatives | Anti-inflammatory [ | 474,387 | 9,518,904 | 25,791 | |
| L | C7H14N2O4 | 190.095 | 17.63 | C00666 | ns | Amino acid | N/A | 0 | 115,608 | 0 |
| N6,N6,N6-Trimethy | C9H20N2O2 | 188.152 | 21.12 | C03793 | ns | Cardiovascular disease biomarker [ | 462,527 | 208,659 | 12,965 | |
| Orotate | C5H4N2O4 | 156.017 | 10.27 | C00295 | ns | Pyrimidinecarboxylic acids | N/A | 0 | 437,266 | 0 |
| Pterin | C6H5N5O | 163.049 | 10.30 | C00715 | ns | Pterins and derivatives | Biomarker of exercise-induced stress [ | 0 | 460,935 | 0 |
| Pyridoxal | C8H9NO3 | 167.058 | 7.46 | C00250 | ns | Pyridoxals and derivatives | N/A | 323,537 | 0 | 10,226 |
| 5-Oxoproline | C5H7NO3 | 129.042 | 9.82 | C01879 | ns | Alpha amino acids and derivatives | Promotes oxidative stress in neuropathology [ | 0 | 32,495,730 | 0 |
| 2,5-Dihydroxybenzoate | C7H6O4 | 154.026 | 8.30 | C00628 | ns | Hydroxybenzoic acid derivatives | Anti-cancer activity [ | 0 | 1,377,617 | 0 |
| 4-Trimethylammoniobutanoate | C7H15NO2 | 145.110 | 12.25 | C01181 | ns | Straight chain fatty acids | N/A | 217,954 | 0 | 2264 |
a Formula; b Chemical taxonomy = Formula and chemical taxonomy for compounds were taken from human metabolome database (HMDB, http://www.hmdb.ca); c Rt = retention time in minutes; d KEGG ID (http://www.genome.jp/kegg/) contains information on biosynthetic and metabolic pathways of identified compounds; e log 2(FC) is a fold change between NB_SE and TM_SE; Abbreviations: ns = not significant; ID = identity; NB_SE = the somatic extract of infective third-stage larvae (L3) of N. brasiliensis; NB_ESP = the excretory/secretory products (ESP) of N. brasiliensis L3; TM_SE = the somatic extract of T. muris embryonated eggs. Note: peak areas values of media were subtracted from the samples.
Figure 3Volcano plot of untargeted metabolomics analysis of differential features (i.e., 49 MSI-I (Metabolomics Standard Initiative level-1) identified polar metabolites from somatic extracts) between the somatic extract of infective third-stage larvae (L3) of N. brasiliensis (NB_SE) and the somatic extract of T. muris embryonated eggs (TM_SE). The volcano plot displays log2 fold changes versus Benjamini–Hochberg adjusted p-values (−log10 transformed). Features that exhibited an absolute log2 fold change > 2 and an absolute p-value < 0.05 are coloured in pink. Most significant metabolites are labelled with the corresponding name.
Figure 4Principal component analysis scores plot for three sample groups, i.e., the somatic extract of infective third-stage larvae (L3) of N. brasiliensis (NB_SE) (green), the excretory/secretory products (ESP) of N. brasiliensis L3 (NB_ESP) (red), and the somatic extract of T. muris embryonated eggs (TM_SE) (blue) with five replicates each. Parentheses on each axis explain the amount of variance. Media (QC_Media) and pooled quality control (QC_P) values were excluded from the analysis, as they were subtracted from the samples.
Figure 5Hierarchical clustering analysis (HCA) of the three samples (the somatic extract of infective third-stage larvae (L3) of N. brasiliensis (NB_SE), the excretory/secretory products (ESP) of N. brasiliensis L3 (NB_ESP), and the somatic extract of T. muris embryonated eggs (TM_SE)) showing discrimination between the sample types and differential abundances of 55 polar metabolites. Each column represents sample groups with their replicates, and each row represents the expression profile of a metabolite across sample groups. The scale bar represents the normalised intensity of metabolites, where blue indicates a decrease/low and red an increase/high. Media (QC_Media) and pooled quality control (QC_P) values were excluded from the analysis, as they were subtracted from the samples.
Figure 6Distribution of putative lipids by lipid classes: (A) in the somatic extract of infective third-stage larvae (L3) of N. brasiliensis (NB_SE); (B) in the excretory/secretory products (ESP) of N. brasiliensis L3 (NB_ESP); (C) in the somatic extract of T. muris embryonated eggs (TM_SE).
Figure 7Volcano plot of the untargeted lipidomics analysis of differentially regulated features between the somatic extract of infective third-stage larvae (L3) of N. brasiliensis (NB_SE) and the somatic extract of T. muris eggs (TM_SE). The volcano plot displays log2 fold changes versus Benjamini–Hochberg adjusted p-values (-log10 transformed). Features that exhibited an absolute log2 fold change > 2 and an absolute p-value < 0.05 are coloured in pink. Most significant features which could be structurally annotated are labelled with the corresponding name. Gray dots represent features that were not significantly altered (having fold change less than 2). The further its position away from the (0,0), the more significant the lipid is.
Figure 8Principal component analysis scores plot comparing LC-MS metabolomic profiles for the lipids among three sample groups: the somatic extract of infective third-stage larvae (L3) of N. brasiliensis (NB_SE) (green), the excretory/secretory products of N. brasiliensis L3 (NB_ESP) (red), and the somatic extract of T. muris embryonated eggs (TM_SE) (blue) with five replicates each. The amount of variance explained is shown in parentheses on each axis. Media (QC_Media) and pooled quality control (QC_P) values were excluded from the analysis, as they were subtracted from the samples.
Figure 9Hierarchical clustering analysis (HCA) of the three samples (the somatic extract of infective third-stage larvae (L3) of N. brasiliensis (NB_SE), the excretory/secretory products (ESP) of N. brasiliensis L3 (NB_ESP), and the somatic extract of T. muris embryonated eggs (TM_SE)), showing discrimination between the sample types and differential abundances of 350 putative lipids. Each row represents putative lipids, and each column represents the biological replicates of an individual sample group. The scale bar represents the normalised intensity of metabolites, where blue colour indicates low/decrease, and red colour indicates high/increase. Media (QC_Media) and pooled quality control (QC_P) values were excluded from the analysis, as they were subtracted from the samples. Note: Heat-map was purposefully generated on all 350 putative lipids to show the overall pattern between the sample groups. For specific lipid details with peak areas, refer to Supplementary Table S2.
Figure 10Distribution of common and unique metabolites among the three sample groups: the somatic extract of infective third-stage larvae (L3) of N. brasiliensis (NB_SE), the excretory/secretory products (ESP) of N. brasiliensis L3 (NB_ESP), and the somatic extract of T. muris embryonated eggs (TM_SE). (A) MSI-I identified polar metabolites; (B) MSI-II identified lipids.
Putative lipids unique to infective stages of N. brasiliensis (L3) and T. muris (embryonated eggs).
| Putative Lipids | Formula a | Mass ( | Rt (min) c | Chemical Taxonomy b | LipidMAPS ID d | Peak Areas (mz/rt) | ||
|---|---|---|---|---|---|---|---|---|
| NB_SE | NB_ESP | TM_SE | ||||||
| DG(41:7) | C44H72O5 | 680.536 | 16.05 | Glycerolipids | LMGL02010545 | 124,404 | 0 | 0 |
| FA hydroxy(12:0) dodecanoic acid | C12H24O3 | 238.155 | 2.19 | Fatty Acyls | NA | 0 | 0 | 51,014 |
| LacCer(d38:0) | C50H97NO13 | 919.696 | 18.98 | Sphingolipids | LMSP05010122 | 139,285 | 0 | 0 |
| LacCer(d40:0) | C52H101NO13 | 947.727 | 20.22 | Sphingolipids | LMSP05010124 | 182,175 | 0 | 0 |
| LysoPE(22:2) | C27H52NO7P | 533.350 | 4.84 | Glycerophospholipids | LMGP02050024 | 136,295 | 0 | 0 |
| PE-Cer(d40:1) | C42H85N2O7P | 760.610 | 13.49 | Sphingolipids | LMSP03020086 | 117,114 | 0 | 0 |
| PE-Cer(d38:1) | C40H81N2O7P | 732.579 | 12.26 | Sphingolipids | LMSP03020064 | 112,168 | 0 | 0 |
| PA(25:0) | C28H55O8P | 550.364 | 12.05 | Glycerophospholipids | LMGP10010001 | 0 | 0 | 374,621 |
| PA(26:0) | C29H57O8P | 564.379 | 12.58 | Glycerophospholipids | LMGP10010980 | 0 | 0 | 1,921,006 |
| PC(36:7) | C44H74NO8P | 775.514 | 10.73 | Glycerophospholipids | LMGP01012100 | 105,372 | 0 | 0 |
| PC(P-32:2) | C40H76NO7P | 713.536 | 13.07 | Glycerophospholipids | NA | 657,868 | 0 | 0 |
| PC(P-36:2) | C44H84NO7P | 769.599 | 14.95 | Glycerophospholipids | LMGP01030137 | 138,297 | 0 | 0 |
| PE(28:2) | C33H62NO8P | 631.422 | 7.68 | Glycerophospholipids | LMGP02011238 | 127,324 | 0 | 0 |
| PE(48:2) | C53H102NO8P | 911.734 | 20.75 | Glycerophospholipids | LMGP02010893 | 466,471 | 0 | 0 |
| PE(40:5) | C45H80NO8P | 815.542 | 12.76 | Glycerophospholipids | LMGP02010893 | 483,243 | 0 | 0 |
| PE(48:1) | C53H104NO8P | 913.751 | 21.37 | Glycerophospholipids | NA | 1,154,195 | 0 | 0 |
| PE(O-20:0) | C25H54NO6P | 495.370 | 7.71 | Glycerophospholipids | LMGP02060005 | 108,008 | 0 | 0 |
| PE(P-20:0) | C25H52NO6P | 493.354 | 7.86 | Glycerophospholipids | LMGP02070004 | 375,557 | 0 | 0 |
| PE(P-36:4) | C41H74NO7P | 723.521 | 12.51 | Glycerophospholipids | LMGP02030093 | 195,178 | 0 | 0 |
| PE(P-36:5) | C41H72NO7P | 721.504 | 11.93 | Glycerophospholipids | LMGP02030028 | 87,036 | 0 | 0 |
| PE(P-38:6) | C43H74NO7P | 747.519 | 12.36 | Glycerophospholipids | LMGP02030001 | 308,137 | 0 | 0 |
| PG(36:1) | C42H81O10P | 776.557 | 11.98 | Glycerophospholipids | LMGP04010037 | 699,995 | 0 | 0 |
| PI(37:6) | C46H77O13P | 868.512 | 9.51 | Glycerophospholipids | LMGP06010790 | 119,218 | 0 | 0 |
| PI(38:7) | C47H77O13P | 880.512 | 9.44 | Glycerophospholipids | LMGP06010792 | 168,877 | 0 | 0 |
| PI(P-37:2) | C46H85O12P | 860.576 | 11.78 | Glycerophospholipids | LMGP06030067 | 94,153 | 0 | 0 |
| PS(28:2) | C34H62NO10P | 675.412 | 6.97 | Glycerophospholipids | LMGP03010919 | 253,811 | 0 | 0 |
| PS(36:4) | C42H74NO10P | 783.506 | 10.48 | Glycerophospholipids | LMGP03010038 | 141,937 | 0 | 0 |
| PS(36:5) | C42H72NO10P | 781.491 | 10.06 | Glycerophospholipids | LMGP03010654 | 115,385 | 0 | 0 |
| PS(O-38:0) | C44H88NO9P | 805.621 | 15.40 | Glycerophospholipids | LMGP03020051 | 86,582 | 0 | 0 |
| PS(O-34:0) | C40H80NO9P | 749.558 | 12.46 | Glycerophospholipids | LMGP03020043 | 0 | 0 | 1883 |
| SM(d41:2) | C46H91N2O6P | 844.667 | 14.55 | Sphingolipids | LMSP03010074 | 29,023 | 0 | 0 |
| SM(d42:2) | C47H93N2O6P | 812.676 | 15.24 | Sphingolipids | LMSP03010007 | 78,211 | 0 | 0 |
a Formula; b Chemical taxonomy = Formula and chemical taxonomy for compounds were taken from LipidMAPS database (https://www.LipidMAPS.org); c Rt = retention time in minutes; d LIPIDMAPS ID (https://www.LipidMAPS.org) contains information on biosynthetic and metabolic pathways of identified lipids; Abbreviations: ID = identity; NB_SE = the somatic extract of infective third-stage larvae (L3) of N. brasiliensis; NB_ESP = the excretory/secretory products (ESP) of N. brasiliensis L3; TM_SE = the somatic extract of T. muris embryonated eggs.